Novartis Ag

Arrowhead Pharmaceuticals, Inc.

Arrowhead Research Corporation

Henry Luke Danahay

Pamela Tan

Anke Geick

Emma Hickman

Gino Van Heeke

Hans-Peter Vornlocher

Hans Peter Vornlocher

Ian Francis Hassan

Jeremy Guy Clarke

Aron Brandon Jaffe

The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.

RNAi inhibition of alpha-ENaC expression

The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease. We found that inflammatory cytokine treatment resulted in a skewing of basal cell differentiation towards a goblet cell fate, culminating in enhanced mucus production. We identified Notch2 as a key node required for cytokine-induced goblet cell metaplasia in vitro and in vivo Inhibition of Notch2 prevents goblet cell metaplasia induced by a broad range of stimuli, which is a hallmark of many respiratory diseases.

Notch2 binding molecules for treating respiratory diseases

A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.

Combination of formoterol and mometasone furoate for asthma

Combinations of formoterol and mometasone furoate for asthma

Growing community of inventors

Horsham, United Kingdom

Henry Luke Danahay